Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2006.24.18_suppl.4143PMID 27954150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

  2022cites this paper
• Analysis of the Medication Rules of Traditional Chinese Medicines (TCMs) in Treating Liver Cancer and Potential TCMs Exploration

  2022cites this paper
• New landscapes and horizons in hepatocellular carcinoma therapy

  2020cites this paper
• Liver and Bile Duct Cancer

  2020cites this paper
• Neue Standards in der Therapie des fortgeschrittenen hepatozellulären Karzinoms

  2019cites this paper
• The future is now: beyond first line systemic therapy in hepatocellular carcinoma

  2019cites this paper
• Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-β-induced epithelial to amoeboid transition

  2019cites this paper
• Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies

  2019cites this paper
• Precision diagnosis and treatment of liver cancer in China.

  2018cites this paper
• Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies

  2018cites this paper
• MOLECULAR INSIGHTS INTO HEPATOCELLULAR CARCINOMA WITH BIOMARKER IDENTIFICATION: FROM BIRTH TO TREATMENT

  2016cites this paper
• Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair

  2016cites this paper
• Heterogeneity of liver cancer and personalized therapy.

  2016cites this paper
• Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

  2015cites this paper
• Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

  2015cites this paper
• Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.

  2015cites this paper
• EGFR Signaling in Liver Diseases

  2015cites this paper
• Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement

  2015cites this paper
• Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

  2014cites this paper
• Targeted Therapies in Hepatocellular Carcinoma

  2014cites this paper
• Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.

  2014cites this paper
• Molecular Targeted Therapy in Hepatocellular Carcinoma: From Biology to Clinical Practice and Future

  2014cites this paper
• Molecular Targeted Therapy of Hepatocellular Carcinoma

  2013cites this paper
• Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma

  2013cites this paper
• New agents on the horizon in hepatocellular carcinoma

  2013cites this paper
• Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

  2013cites this paper
• The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

  2013cites this paper
• Targeted agents and systemic therapy in hepatocellular carcinoma.

  2013cites this paper
• Identification of signaling pathways related to drug efficacy in hepatocellular carcinoma via integration of phosphoproteomic, genomic and clinical data

  2013cites this paper
• Systemische Therapie des hepatozellulären Karzinoms

  2013cites this paper
• New Pharmacological Developments in the Treatment of Hepatocellular Cancer

  2012cites this paper
• Pathways and targets in hepatocellular carcinoma

  2012cites this paper
• Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.

  2012cites this paper
• Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics

  2012cites this paper
• Growth factor pathways in development and progression of hepatocellular carcinoma.

  2012cites this paper
• Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.

  2012cites this paper
• Liver cancer: Targeted future options.

  2011cites this paper
• A Review of Targeted Therapies in the Management of Advanced-stage Hepatocellular Carcinoma

  2011cites this paper
• Targeted Therapy in Hepatocellular Carcinoma

  2011cites this paper
• The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms.

  2011cites this paper
• Targeted Therapies for Hepatocellular Carcinoma

  2011cites this paper
• Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

  2011cites this paper
• Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2011cites this paper
• Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.

  2011cites this paper
• Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors

  2011cites this paper
• [New perspectives for radiosensitization in hepatocellular carcinoma: a review of mechanisms involved in liver oncogenesis].

  2011cites this paper
• EGF receptor inhibitors for hepatocellular carcinoma

  2011cites this paper
• Novel molecular therapies in hepatocellular carcinoma

  2011cites this paper
• Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma

  2011cites this paper
• Targeting metastatic upper gastrointestinal adenocarcinomas.

  2011cites this paper
• Leczenie interferujące z funkcją EGFR u chorych na nowotwory złośliwe przełyku, żołądka, trzustki, wątroby i dróg żółciowych Therapy interfering with EGFR activation in patients with cancers of oesophagus, stomach, pancreas, liver and bile ducts

  2011cites this paper
• Systemic therapy in hepatocellular carcinoma.

  2011cites this paper
• Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.

  2011cites this paper
• Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib.

  2010cites this paper
• Neue Standards in der Therapie des fortgeschrittenen hepatozellulären Karzinoms

  2010cites this paper
• Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

  2010cites this paper
• Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?

  2010cites this paper
• Tyrosine kinase inhibitors to treat liver cancer

  2010cites this paper
• Current problems with systemic treatment of advanced hepatocellular cancer.

  2010cites this paper
• Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

  2010cites this paper
• Developing better treatments in hepatocellular carcinoma

  2010cites this paper
• Molecularly targeted therapy in hepatocellular carcinoma.

  2010cites this paper
• Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib

  2010cites this paper
• Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan

  2010cites this paper
• Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

  2010cites this paper
• The role of signaling pathways in the development and treatment of hepatocellular carcinoma

  2010cites this paper
• Novel inhibitors in development for hepatocellular carcinoma

  2010cites this paper
• Current approach in the treatment of hepatocellular carcinoma.

  2010cites this paper
• Targeted therapy of hepatocellular cancer

  2010cites this paper
• Latest developments in targeted therapy for hepatocellular carcinoma

  2010cites this paper
• Evolving treatments of virus-associated HCC: new targets and drugs.

  2010cites this paper
• [Treatment of advanced hepatocellular carcinoma].

  2010cites this paper
• Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

  2010cites this paper
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

  2010cites this paper
• Actitud a seguir ante la detección de una lesión focal inferior o igual a 2 cm de tamaño en un paciente con cirrosis hepática

  2010cites this paper
• Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma

  2010cites this paper
• Novel systemic approaches to treatment of HCC

  2010cites this paper
• New drugs for the treatment of hepatocellular carcinoma

  2009cites this paper
• The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer

  2009cites this paper
• Targeted therapy for hepatocellular carcinoma

  2009cites this paper
• A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

  2009cites this paper
• Systemic Therapies in Hepatocellular Carcinoma

  2009cites this paper
• Molecularly targeted therapy for hepatocellular carcinoma

  2009cites this paper
• Management of advanced hepatocellular carcinoma in the era of targeted therapy

  2009cites this paper
• Das hepatozelluläre Karzinom aus der Sicht des Internisten und des Chirurgen

  2009cites this paper
• Pathogenesis of hepatocellular carcinoma and molecular therapies

  2009cites this paper
• Vascular endothelial growth factor in the management of hepatocellular carcinoma

  2009cites this paper
• Targeting Signaling Pathways in Cancer Therapy

  2009cites this paper
• Targeted agents for the systemic treatment of advanced hepatocellular carcinoma

  2009cites this paper
• Targeted therapies for the systemic treatment of advanced hepatocellular carcinoma

  2009cites this paper
• [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].

  2009cites this paper
• Die medikamentöse Therapie des HCC mit Sorafenib – der Beginn einer neuen Ära in der Behandlung des HCC

  2009cites this paper
• Molecular therapy for the treatment of hepatocellular carcinoma

  2008cites this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cites this paper
• Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy

  2008cites this paper
• Systemic Therapy for Hepatocellular Carcinoma

  2008cites this paper
• Targeted therapies for hepatocellular carcinoma.

  2008cites this paper
• Molecular targeted therapy for hepatocellular carcinoma

  2008cites this paper
• Successful targeted therapies for hepatocellular carcinoma: are we really getting there?

  2008cites this paper
• Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

  2008cites this paper